MON-554 Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy

Background: Historical data suggests differentiated thyroid cancer (DTC) patients (pts) with brain metastases (mets) have overall survival (OS) of approximately 1 year; other reports refer median OS of 33months. Little is known about the mutation profile these pts. The TCGA indicates a median of 1 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Agosto Salgado, Sarimar, Waguespack, Steven, Cote, Gilbert, Hess, Kenneth, Habra, Mouhammed, Jimenez, Camilo, Hu, Mimi, Sherman, Steven, Busaidy, Naifa, Dadu, Ramona, Tatsui, Claudio, McCutcheon, Ian, Grubbs, Elizabeth, Williams, Michelle, Shah, Komal, Cabanillas, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551022/
http://dx.doi.org/10.1210/js.2019-MON-554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551022/
http://dx.doi.org/10.1210/js.2019-MON-554

Ejemplares similares